burosumab-twza (crysvita) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL Drugs@FDA

Active Ingredient History

NOW
  • Now
Burosumab, sold under the brand name Crysvita, is a human monoclonal antibody medication for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia. Burosumab was approved by the FDA for its intended purpose, in patients aged one year and older, in April 2018. The FDA approval fell under both the breakthrough therapy and orphan drug designations. It was approved for use in the European Union in February 2018.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$2556.3900 - $10183.8700
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

burosumab | burosumab-twza | krn23 | krn-23

Organizations (10)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Chronic Pain (Phase 3)

Familial Hypophosphatemic Rickets (Phase 4)

Genetic Diseases, X-Linked (Phase 3)

Hypophosphatemia (Phase 3)

Neoplasms (Phase 2)

Nevus (Phase 4)

Rare Diseases (Phase 4)

Rickets, Hypophosphatemic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue